Page last updated: 2024-11-06

tedisamil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tedisamil : A member of the class of diazabicyclononanes that is (1s,5s)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65825
CHEMBL ID113461
CHEMBL ID2111110
CHEBI ID134747
SCHEMBL ID157918
SCHEMBL ID10025758
MeSH IDM0166562

Synonyms (34)

Synonym
pulzium
spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane), 3',7'-bis(cyclopropylmethyl)-
3',7'-bis(cyclopropylmethyl)spiro(cyclopentane-1,9'-(3,7)diazabicyclo(3.3.1)nonane)
tedisamil [inn]
tedisamil
kc-8857
kc 8857
tedisamilum [inn-latin]
D06652
90961-53-8
tedisamil (usan)
3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane]
gtpl2567
kc8857
(1s,5s)-3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
tedisamilum
CHEBI:134747
bdbm50088367
CHEMBL113461
a5vay2u3r8 ,
tedisamil [usan:inn:ban]
unii-a5vay2u3r8
tedisamil [usan]
tedisamil [who-dd]
tedisamil [mi]
tedisamil [mart.]
SCHEMBL157918
CTIRHWCPXYGDGF-UHFFFAOYSA-N
SCHEMBL10025758
DTXSID30238334
CHEMBL2111110
Q3982536
DB06200
AKOS040746397

Research Excerpts

Overview

Tedesamil is an unusual antifibrillatory compound that has a novel mechanism of action by inhibiting the transient outward current (Ito) and the repolarizing potassium currents in the sinoatrial node. Tedisamil has shown clinical efficacy in angina pectoris.

ExcerptReferenceRelevance
"Tedisamil is an unusual antifibrillatory compound that has a novel mechanism of action by inhibiting the transient outward current (Ito) and the repolarizing potassium currents in the sinoatrial node."( Tedisamil in coronary disease: additional benefits in the therapy of atrial fibrillation?
Opie, LH, 2003
)
2.48
"Tedisamil is a complex class 3 agent, blocking multiple channels."( Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Singh, S, 2004
)
1.04
"Tedisamil is a novel antiarrhythmic drug with predominantly class III activity. "( Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.
Beckmann, K; Dorian, P; Hohnloser, SH; Kowey, P; Straub, M, 2004
)
2.02
"Tedisamil is a new blocker of K+ currents in cardiac tissues, exerts bradycardic effects and has shown clinical efficacy in angina pectoris. "( Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers.
Démolis, JL; Funck-Brentano, C; Jaillon, P; Martel, C; Sachse, A; Weimann, HJ, 1997
)
2.13
"Tedisamil is a potassium channel blocking agent known to produce bradycardia and prolong the effective refractory period in man."( Investigation of the potential interaction between terfenadine and tedisamil in human liver microsomes.
Bader, A; Borlak, JT; Cameron, GA; Hawksworth, GM; McCully, S, 1998
)
1.26
"Tedisamil is a new bradycardic agent proven to exert anti-ischemic and antiarrhythmic effects by blockade of the different cardiac and vascular K+ currents."( Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
Haberbosch, W; Mitrovic, V; Oehm, E; Pitschner, H; Thormann, J, 1998
)
2
"1. Tedisamil is a new antiarrhythmic drug with predominant class III action. "( Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes.
Amos, GJ; Himmel, HM; Li, Q; Metzger, F; Ravens, U; Wettwer, E, 1998
)
1.24
"Tedisamil is a new bradycardic agent proven to exert antiischemic and antiarrhythmic effects by blockade of the cellular cardiac repolarization K+ currents as well as of multiple neuronal and vascular K+ currents (Ito, Ik, and K+ATP)."( Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
Hamm, C; Mitrovic, V; Oehm, E; Pitschner, H; Thormann, J, 2000
)
1.03
"Tedisamil is a bradycardic agent resulting from its ability to inhibit transient outward current (I(to)) in atria."( Tedisamil: master switch of nature?
Doggrell, SA, 2001
)
2.47
"1. Tedisamil is a bradycardiac agent that prolongs the QT interval of the ECG and prevents cardiac arrhythmias. "( Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.
Barrett, TD; Driscoll, EM; Fischbach, PS; Hennan, JK; Lucchesi, BR; O'Neill, BP, 2001
)
2.37
"Tedisamil is an experimental bradycardic agent possessing action potential-prolonging effects. "( Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.
Barrett, TD; Fischbach, PS; Goyal, R; Hennan, JK; Lucchesi, BR; Syed, ZA; Tran, BC, 2001
)
1.98
"Tedisamil is a new bradycardic agent with an inhibitory action on K+ channels in cardiac muscle, and secondary beneficial effects in experimentally induced cardiac ischemia. "( Tedisamil inhibits the delayed rectifier K+ current in single smooth muscle cells of the guinea-pig portal vein.
Kreye, VA; Pfründer, D, 1992
)
3.17

Effects

Tedisamil has a rapid onset of action leading to conversion within 30 to 40 min in the majority of responders. It is a selective inhibitor of a fast inactivating transient outward current (i(to,f) in rat ventricular myocytes.

ExcerptReferenceRelevance
"Tedisamil has a rapid onset of action leading to conversion within 30 to 40 min in the majority of responders."( Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.
Beckmann, K; Dorian, P; Hohnloser, SH; Kowey, P; Straub, M, 2004
)
1.3
"Tedisamil has a rapid onset of action leading to conversion within 30 to 40 min in the majority of responders."( Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.
Beckmann, K; Dorian, P; Hohnloser, SH; Kowey, P; Straub, M, 2004
)
1.3
"Tedisamil has been described as a selective inhibitor of a fast inactivating transient outward current (i(to,f)) in rat ventricular myocytes. "( Different inhibition patterns of tedisamil for fast and slowly inactivating transient outward current in rat ventricular myocytes.
Berger, F; Borchard, U; Hafner, D; Weis, TM, 1998
)
2.02

Treatment

Tedisamil treatment may implicate coadministration with class IV antiarrhythmics such as verapamil, a P-glycoprotein inhibitor. Tedisamill-treated animals exhibited a 100% compared with a 25% survival rate in the control group (p < 0.05)

ExcerptReferenceRelevance
"Tedisamil treatment may implicate coadministration with class IV antiarrhythmics such as verapamil, a P-glycoprotein inhibitor."( Clinically important interaction between tedisamil and verapamil.
Bosch, JJ; Burggraaf, J; Cohen, AF; Dijkmans, AC; Kemme, MJ; Schoemaker, RC; van Haarst, AD; Weimann, HJ, 2009
)
1.34
"Tedisamil-treated animals exhibited a 100% compared with a 25% survival rate in the control group (p < 0.05)."( Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation.
Abreu, JN; Borlak, J; Driscoll, EM; Friedrichs, GS; Lucchesi, BR, 1998
)
1.29
"Pretreatment with tedisamil widened QT50 (p < 0.05), and this effect was not attenuated by combined treatment with cromakalim."( Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats.
Curtis, MJ; Hearse, DJ; Rees, SA; Tsuchihashi, K, 1993
)
0.61

Dosage Studied

A 1 to 20 microM dosage of tedisamil caused marked prolongation of the action potential in isolated rat ventricular myocytes, mimicking its reported effects on multicellular rat heart preparations. In a separate series of experiments in which normal ventricular tissue was electrically stimulated, 2 micro mol kg (-1) min(-1) lidocaine produced a leftward shift in the dose-response curve for tedisAmil's effect on effective refractory period.

ExcerptRelevanceReference
" A 1 to 20 microM dosage of tedisamil caused marked prolongation of the action potential in isolated rat ventricular myocytes, mimicking its reported effects on multicellular rat heart preparations."( Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells.
Cleemann, L; Dukes, ID; Morad, M, 1990
)
2.02
" A dose-response trial was performed in the vagal AF group as well as in a second group of three dogs that underwent chronic fibrillatory pacing."( Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.
Barrett, TD; Fischbach, PS; Goyal, R; Hennan, JK; Lucchesi, BR; Syed, ZA; Tran, BC, 2001
)
0.54
" In a separate series of experiments in which normal ventricular tissue was electrically stimulated, 2 micro mol kg(-1) min(-1) lidocaine produced a leftward shift in the dose-response curve for tedisamil's effect on effective refractory period (P<0."( Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats.
Barrett, TD; Sarraf, G; Walker, MJ, 2003
)
1.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium channel protein type 1 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00232.82969.0000AID1207173
Sodium channel protein type 4 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00013.507510.0000AID1207173
Sodium channel protein type 7 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.03603.73359.0000AID1207173
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)2.50000.00091.901410.0000AID1207232
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00033.64849.2000AID1207173
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00602.77499.0000AID1207173
Sodium channel protein type 2 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00003.740110.0000AID1207173
Sodium channel protein type 3 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00532.80859.0000AID1207173
Sodium channel protein type 11 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.03004.36959.0000AID1207173
Sodium channel protein type 8 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00113.47059.0000AID1207173
Sodium channel protein type 10 subunit alphaHomo sapiens (human)IC50 (µMol)20.00000.00803.17529.0000AID1207173
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (115)

Processvia Protein(s)Taxonomy
sodium ion transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
adult walking behaviorSodium channel protein type 1 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potential propagationSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuromuscular process controlling postureSodium channel protein type 1 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 1 subunit alphaHomo sapiens (human)
establishment of localization in cellSodium channel protein type 1 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 1 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
osmosensory signaling pathwaySodium channel protein type 7 subunit alphaHomo sapiens (human)
response to bacteriumSodium channel protein type 7 subunit alphaHomo sapiens (human)
cellular homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 7 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuron apoptotic processSodium channel protein type 2 subunit alphaHomo sapiens (human)
memorySodium channel protein type 2 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 2 subunit alphaHomo sapiens (human)
dentate gyrus developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 2 subunit alphaHomo sapiens (human)
cellular response to hypoxiaSodium channel protein type 2 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 3 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 3 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
thigmotaxisSodium channel protein type 11 subunit alphaHomo sapiens (human)
acute inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
chronic inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonogenesisSodium channel protein type 11 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to heatSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to xenobiotic stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to high light intensitySodium channel protein type 11 subunit alphaHomo sapiens (human)
protein kinase A signalingSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to auditory stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to prostaglandin ESodium channel protein type 11 subunit alphaHomo sapiens (human)
thermosensory behaviorSodium channel protein type 11 subunit alphaHomo sapiens (human)
mast cell degranulationSodium channel protein type 11 subunit alphaHomo sapiens (human)
cell motilitySodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
reflexSodium channel protein type 11 subunit alphaHomo sapiens (human)
micturitionSodium channel protein type 11 subunit alphaHomo sapiens (human)
skeletal muscle organ developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
artery developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to acetic acid induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to formalin induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
cellular response to coldSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to nitric oxideSodium channel protein type 11 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
action potential initiationSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of itchSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcitonin gene-related peptide receptor signaling pathwaySodium channel protein type 11 subunit alphaHomo sapiens (human)
small intestine smooth muscle contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
peripheral nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 8 subunit alphaHomo sapiens (human)
optic nerve developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 8 subunit alphaHomo sapiens (human)
regulation of heart rateSodium channel protein type 10 subunit alphaHomo sapiens (human)
sensory perceptionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of monoatomic ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 10 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
voltage-gated sodium channel activitySodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 7 subunit alphaHomo sapiens (human)
osmolarity-sensing monoatomic cation channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 2 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 8 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
ATP bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 10 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 1 subunit alphaHomo sapiens (human)
nuclear bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 1 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 1 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 7 subunit alphaHomo sapiens (human)
glial cell projectionSodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 7 subunit alphaHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 2 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 2 subunit alphaHomo sapiens (human)
axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 2 subunit alphaHomo sapiens (human)
paranode region of axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 2 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
sarcoplasmSodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 3 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 11 subunit alphaHomo sapiens (human)
axonal growth coneSodium channel protein type 11 subunit alphaHomo sapiens (human)
C-fiberSodium channel protein type 11 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 11 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 8 subunit alphaHomo sapiens (human)
cell junctionSodium channel protein type 8 subunit alphaHomo sapiens (human)
axonSodium channel protein type 8 subunit alphaHomo sapiens (human)
cytoplasmic vesicleSodium channel protein type 8 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 8 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
presynaptic active zone membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
parallel fiber to Purkinje cell synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
postsynaptic density membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 8 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
axonSodium channel protein type 10 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 10 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
clathrin complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID190449Score value indicates desire effect on heart rate1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80761Sum of the scores of decrease of the sinus rate and selectivity versus the decrease in force of contraction1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80757Score value indicates decrease of the sinus rate1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID232937Selectivity quotient (R&T125/HR75)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID1207232Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1207263Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID190450Score value indicates selectivity against the undesired effect on diastolic blood pressure1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID19457Partition coefficient (logP)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID190451Score value indicates selectivity against the undesired effect on diastolic blood pressure1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80740In vitro activity in guinea pig atria as the functional refractory period (FRP), which is the shortest interval between a double stimulus causing a double contraction.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID232930Selectivity quotient (DAP125/HR75); # means very high (estimated)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80759Score value indicates selectivity versus the decrease in force of contraction1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID181273In vivo activity in anesthetized rat was measured as heart rate which provides information on in vivo bradycardic activity1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80752In vitro activity in guinea pig atria was measured as the peak force of contraction (F) of a stimulated left atrium1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80756Score point for the selectivity versus additional effect FRP.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID1207173Inhibition of Na channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID173633In vivo activity in anesthetized rat was measured as the R alpha T-interval of the rat ECG which reflects the time from ventricular excitation to recovery1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID80750In vitro activity in guinea pig atria was measured as rate of spontaneously beating right atrium (SR) which reflects the activity of the sinus node1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID232931Selectivity quotient (F75/SR75)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID190448Score point for the selectivity versus additional effect R&T interval.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID232934Selectivity quotient (FRP125/SR75)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
AID1346659Mouse Kv1.7 (Voltage-gated potassium channels)1998The Journal of biological chemistry, Mar-06, Volume: 273, Issue:10
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (83)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (4.82)18.7374
1990's45 (54.22)18.2507
2000's33 (39.76)29.6817
2010's1 (1.20)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.58 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (12.94%)5.53%
Reviews11 (12.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (74.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibr [NCT00126022]Phase 30 participants Interventional2004-12-31Completed
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibr [NCT00126074]Phase 30 participants Interventional2004-10-31Completed
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibril [NCT00126061]Phase 30 participants Interventional2004-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]